Patent · US Active

Inhibiting (α-V)(β-6) integrin

US11021480B2 · kind B2 · utility

5Cited by

9References

2Claims

0Family size

Assignee

Morphic Therapeutic, Inc. · US

Inventors

Bryce A. Harrison · Framingham, US
James E. Dowling · Lexington, US
Matthew G. Bursavich · Tuckahoe, US
Dawn M. Troast · Bedford, US
Blaise S. Lippa · Newton, US
Bruce N. Rogers · Belmont, US
Cheng Zhong · Belmont, US
Qi Qiao · San Diego, US
Fu-Yang Lin · Sudbury, US
Brian Sosa · Cambridge, US
Aleksey I. Gerasyuto · Flemington, US
Andrea Bortolato · Cambridge, GB

Key dates

Filing date	Aug 24, 2020
Grant date	Jun 1, 2021
Priority date	—
Expiry date	Aug 24, 2040

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61K9/0053
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Disclosed are small molecule inhibitors of αvβ6 integrin, and methods of using them to treat a number of diseases and conditions.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.